Headquartered in New York, Protheragen Inc. is an integrated biopharmaceutical incubator dedicated to transforming innovative scientific concepts into high-value commercial assets. Our mission is built on a deep understanding of both the U.S. and dynamic emerging markets, enabling us to help life science companies navigate regional complexities and achieve impactful global strategic partnerships.
Protheragen operates through a unique, integrated model that combines technical expertise, capital support, and strategic advisory:
We serve as an accelerator for high-potential projects, moving them from “concept to asset” through a unique management model. This includes strategic development guidance in collaboration with international pharma and research institutions, alongside full-spectrum support for R&D and Intellectual Property protection.
We facilitate the transition from scientific discovery to structured business entities through strategic capital support. While we are not a traditional financial investment institution or a registered fund, we empower projects by providing early-stage capital support, designing financing-ready corporate structures, and connecting innovators with potential buyers and investment partners.
We act as a bridge to the global market, facilitating diverse transaction models including license-out agreements, asset M&A, and co-development. We operate without upfront fees or fixed annual retainers, charging only upon the successful completion of a transaction—truly sharing the risks and rewards with our partners.
We believe that exceptional partnerships begin with deep mutual understanding. If you possess an innovative drug candidate, technology platform, or medical device asset and are ready to realize its value globally, we invite you to take the first step with Protheragen.